Ignite Creation Date:
2024-05-06 @ 5:09 PM
Last Modification Date:
2024-10-26 @ 2:23 PM
Study NCT ID:
NCT05213143
Status:
TERMINATED
Last Update Posted:
2024-04-19
First Post:
2021-12-05
Brief Title:
The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine
Sponsor:
Sumitomo Pharma Suzhou Co Ltd
Organization:
Sumitomo Pharma Suzhou Co Ltd
Study Overview
Official Title:
The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine An Open-label Single-arm And Multi-center Study for 16 Weeks
Status:
TERMINATED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Companys business decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An open-label single-arm and multi-center study for 16 weeks
Detailed Description:
An open-label single-arm and multi-center study for 16 weeks to study the improvement of weight gain in patients with schizophrenia who switched from olanzapine to lurasidone
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None